3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Withdrawn
1
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Uterine Cervical Neoplasms
19
Prostatic Neoplasms
8
Sarcoma
2
Neoplasms
2
Uveitis
1
Uveal Melanoma
1
Uterine Cervical Dysplasia
1
To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
1
Salivary Gland Neoplasms
1
Precancerous Conditions
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Obesity
1
Neurotoxicity Syndromes
1
Liver Neoplasms
1
Hyperthermia
1
Gliosarcoma
1
Glioblastoma
1
Fatigue
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
1
Endometrial Clear Cell Adenocarcinoma
1
Deglutition Disorders
1
Choroid Neoplasms
1
Central Nervous System Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Docetaxel
5
Pemetrexed
4
Capecitabine
4
pembrolizumab
3
Oxaliplatin
3
icotinib
2
Radiation
2
Paclitaxel
2
Gemcitabine
2
Gefitinib
2
Fluorouracil
2
Drug Therapy
2
Chemoradiotherapy
2
Carboplatin
2
sintilimab
1
rucaparib
1
regorafenib
1
olaparib
1
lenvatinib
1
iron isomaltoside 1000
1
ipatasertib
1
iopromide
1
gluconic acid
1
elemene
1
capecitabine-irinotecan combination
1
aumolertinib
1
atezolizumab
1
anlotinib
1
aflutinib
1
XELOX
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Adenocarcinoma
×
Brachytherapy
×
Clear all
NCT01786278
2013-02-07
BRASTEGAC
Medical University of Lublin
Phase 2/3
Unknown
80 enrolled